weight.

5. (Previously presented) The method of claim 4, wherein said noribogaine or its salt is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.

6. (Previously presented) A method of treating a patient to alleviate pain, comprising:

a) administering systemically to said patient an amount of noribogaine or its pharmaceutically acceptable salt; and

b) concomitantly administering systemically to said patient an amount of one or more opioid antagonists; wherein said respective amounts of noribogaine and said one or more opioid antagonists are effective to reduce or eliminate pain in said patient.

7. (Original) The method of claim 6, wherein said opioid antagonist is naloxone, administered to said patient at a dose between 0.05 mg and 0.5 mg for each mg of noribogaine.

8. (Original) The method of claim 6, wherein said opioid antagonist is naltrexone, administered to said patient at a dose of between 0.05 mg and 0.5 mg for each mg of noribogaine.

9. (Original) The method of claim 6, wherein said noribogaine and said opioid antagonist are administered transdermally.

Claims 10-24. Previously cancelled.

25. (Previously presented) A method of treating a patient to alleviate pain without addiction, comprising: administering systemically a pharmaceutical composition consisting essentially of an effective amount of noribogaine or its pharmaceutically acceptable salt to said patient effective to reduce or eliminate pain in said patient.

26. (Previously presented) The method of claim 25, wherein said noribogaine or its salt is the sole analgesic agent in said pharmaceutical composition.

27. (Previously presented) The method of 25, wherein said noribogaine or its salt is administered to said patient at a dose of between 0.1 mg and 100 mg per kg of body weight.